Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,822 across all filing types
Latest filing 2021-04-19 Transaction in Own Shar…
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Transactions in connection with share buy-back program
Transaction in Own Shares Classification · 100% confidence The document is a formal company announcement from Genmab detailing specific transactions executed under a share buy-back program. It provides a table of daily share repurchases, the total value, and the updated treasury share count. This aligns perfectly with the definition of 'Transaction in Own Shares' (POS), which covers reports of a company buying back its own shares.
2021-04-19 English
Transactions in connection with share buy-back program
Transaction in Own Shares Classification · 100% confidence The document is a company announcement detailing specific transactions executed under a share buy-back program. It provides a table of daily share repurchases, total values, and the updated treasury share position. This aligns perfectly with the definition of 'Transaction in Own Shares' (POS), which covers reports of a company buying back its own shares.
2021-04-19 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The provided document text consists almost entirely of tables showing volume, price, venue (XCSE), and time stamps for trades involving the entity 'Genmab'. This structure is characteristic of regulatory filings related to insider transactions or significant shareholding changes, often reported to stock exchanges. The presence of specific transaction codes (implied by the single-digit/two-digit numbers in the 'Volume' column, which often map to transaction types in regulatory feeds, although not explicitly defined here) and the focus on daily trading activity strongly suggests insider dealing or share movement reporting. Given the options, 'Director's Dealing' (DIRS) is the most appropriate classification for documents detailing individual share transactions by insiders. It is not a comprehensive financial report (10-K, IR, ER), nor is it a general announcement (RPA, RNS).
2021-04-19 English
6-K/A
Foreign Filer Report
2021-04-15 English
6-K
Foreign Filer Report
2021-04-13 English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing Classification · 100% confidence The document is a formal notification of transactions in company shares and linked securities (Restricted Stock Units and Warrants) by a person discharging managerial responsibilities (Tahamtan Ahmadi, EVP & Chief Medical Officer). It explicitly cites Article 19 of Regulation No. 596/2014 on Market Abuse, which is the standard regulatory framework for reporting insider/director dealings. This fits the definition of 'Director's Dealing' (DIRS).
2021-04-13 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.